Mind-NRG Successfully Completes 6 Million Euro (~8 Million USD) Series B Financing  
9/4/2013 12:14:55 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GENEVA, Switzerland--(BUSINESS WIRE)--Mind-NRG, the Swiss-based company focusing on developing neuregulins to treat neurodegenerative diseases, announces the close of its Series B financing raising 6 Million EUR (~8 Million USD). The financing was led by new investor LRM, a Belgian based investor specialising in Life Sciences, along with existing investor and leading venture capital firm Index Ventures. Mind-NRG, created in 2010, is investigating the use of neuregulins in treating a variety of neurological and psychiatric disorders. The compounds are neurotrophic factors that have disease modifying potential and naturally cross the blood-brain barrier. In particular, Mind-NRG is developing NRG-101 to treat the early-stages of neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease, as well as schizophrenia.

Help employers find you! Check out all the jobs and post your resume.